InvestmentJul 27, 2026, 08:32 AM
Entera Bio Secures $275M Private Placement; Funds EB613 Phase 3
AI Summary
Entera Bio Ltd. announced an oversubscribed private placement financing, expected to generate approximately $275 million in gross proceeds. The financing, led by BVF Partners L.P., is anticipated to extend the company's cash runway into 2030 and fully fund the Phase 3 registrational studies for EB613, its oral osteoporosis treatment. Additionally, the proceeds will advance EB612 into Phase 1 development and support general corporate purposes.
Key Highlights
- Secured approximately $275 million in gross proceeds from an oversubscribed private placement.
- Financing led by existing investor BVF Partners L.P. with participation from new investors.
- Expected to extend the Company's cash runway into 2030.
- Fully funds Phase 3 registrational studies for EB613, an oral osteoporosis treatment.
- Issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants.
- Purchase price per ordinary share was $2.04.
- BVF Partners L.P. granted the right to designate two directors to the board.
- Funds EB612, an oral hypoparathyroidism candidate, into Phase 1 development.
Price Impact
More from ENTX